The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Abstract
Varenicline, a new nicotinic ligand based on the structure of cytisine, has recently been approved by the U.S. Food and Drug Administration for use as a smoking cessation aid. Varenicline has been shown to be a partial agonist of alpha4beta2 receptors, and in equilibrium binding assays, it is highly selective for the alpha4beta2 receptor. In this study, we have examined the functional activity of varenicline at a variety of rat neuronal nicotinic receptors expressed in Xenopus laevis oocytes and assayed under two-electrode voltage clamp. We also find that varenicline is a potent, partial agonist at alpha4beta2 receptors, with an EC50 of 2.3 +/- 0.3 microM and an efficacy (relative to acetylcholine) of 13.4 +/- 0.4%. Varenicline has lower potency and higher efficacy at alpha3beta4 receptors, with an EC50 of 55 +/- 8 microM and an efficacy of 75 +/- 6%. Varenicline also seems to be a weak partial agonist at alpha3beta2 and alpha6-containing receptors, with an efficacy <10%. It is remarkable that varenicline is a potent, full agonist at alpha7 receptors with an EC50 of 18 +/- 6 microM and an efficacy of 93 +/- 7% (relative to acetylcholine). Thus, whereas varenicline is a partial agonist at some heteromeric neuronal nicotinic receptors, it is a full agonist at the homomeric alpha7 receptor. Some combination of these actions may be involved in the mechanism of varenicline as a smoking cessation aid.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline is a partial agonist of α4/β2* nAChRs (Coe et al., 2005), but also activates α7-type nAChRs (Mihalak et al., 2006).”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Mihalak et al., 2006
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Mihalak et al., 2006
In the citing paper
“the high-affinity ␣42 partial agonist varenicline also has moderate affinity for other nAChRs and acts as a partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Mihalak et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [6]
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [6]
In the citing paper
“It acts as a partial agonist at α3β4-, α2-, and α6-containing nAChRs, and a full agonist at α7 nAChRs [238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [238]
In the citing paper
“It is a derivative of cytisine, a plant alkaloid with selective affinity and partial agonism for α4β2 nAChRs [236–238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [238]
In the citing paper
“It is a derivative of cytisine, a plant alkaloid with selective affinity and partial agonism for α4β2 nAChRs [236–238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [237]
In the citing paper
“subsequent work showed that varenicline had a significant effect at ␣7 nAChRs, ␣34* nAChRs, and 5-hydroxytryptamine type 3 receptors”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Mihalak et al., 2006
In the citing paper
“varenicline, a partial agonist of the α4β2 nAChRs and a full α7 agonist developed to aid smoking cessation in humans (Mihalak, Carroll, & Luetje, 2006), has also been found to have antidepressant effects in the FST (Rollema et al., 2009).”
From Nicotine addiction and psychiatric disorders (2015) · cites this paper as Mihalak et al., 2006
Citations
Cites
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Nicotinic Receptors at the Amino Acid Level
Corringer, P., Novère, N. G. L., & Changeux, J. (2000) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.431 · Cited by 832
Luetje, C., & Patrick, J. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-03-00837.1991 · Cited by 558
Jensen, A. A., Frølund, B., Liljefors, T., & Krogsgaard‐Larsen, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040219e · Cited by 549
Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., & Johnson, E. C. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36376-1 · Cited by 405
Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. C., & Grady, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1526 · Cited by 401
Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., & Johnson, E. C. (1997) · PubMed · Cited by 392
Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit
Papke, R. L., & Heinemann, S. F. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09896-7 · Cited by 259
Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis
Papke, R. L., & Porter Papke, J. K. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704833 · Cited by 249
Human α6 AChR subtypes: subunit composition, assembly, and pharmacological responses
Kuryatov, A., Olale, F., Cooper, J., Choi, C. H., & Lindstrom, J. M. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00144-1 · Cited by 224
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 583
Evaluation of the cardiovascular effects of varenicline in rats
Selçuk, E. B., Süngü, M., Parlakpınar, H., Ermiş, N., Taşlıdere, E., Vardı, N., Yalçınsoy, M., Sağır, M., Polat, A., Karataş, M., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s92268 · Cited by 31
Hendrickson, L. M., Gardner, P. D., & Tapper, A. R. (2011) · Channels · doi:10.4161/chan.5.2.14409 · Cited by 33
Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial
McRae‐Clark, A. L., Gray, K. M., Baker, N. L., Sherman, B. J., Squeglia, L. M., Sahlem, G. L., Wagner, A. M., & Tomko, R. L. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109111 · Cited by 30
Paterson, N. E., Min, W., Hackett, A., Lowe, D., Hanania, T., Caldarone, B. J., & Ghavami, A. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.037 · Cited by 30
Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats
Zaniewska, M., McCreary, A. C., Stefański, R., Przegaliński, E., & Filip, M. (2008) · Synapse · doi:10.1002/syn.20564 · Cited by 33
Greene, C. M., Ramsay, H., Wells, R. J., O'Neill, S. J., & McElvaney, N. G. (2010) · Mediators of Inflammation · doi:10.1155/2010/423241 · Cited by 33
Bupropion–varenicline interactions and nicotine self-administration behavior in rats
Hall, B. J., Slade, S. K., Wells, C., Rose, J. E., & Levin, E. D. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.01.009 · Cited by 31
Pacek, L. R., & Crum, R. M. (2014) · Addiction Research & Theory · doi:10.3109/16066359.2014.920013 · Cited by 30
Treatment of Ataxia and Imbalance With Varenicline (Chantix)
Zesiewicz, T. A., & Sullivan, K. L. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31818736a9 · Cited by 31
Smucny, J., Stevens, K. E., Olincy, A., & Tregellas, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.77 · Cited by 28
Cholinergic Receptors and Addiction
Papke, R. L., Brunzell, D. H., & Biasi, M. D. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_139 · Cited by 30
Chang, Y., Banerjee, J., Dowell, C., Wu, J., Gyanda, R., Houghten, R. A., Toll, L., McIntosh, J. M., & Armishaw, C. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500183r · Cited by 30
Alterations in the expression of neuronal chloride transporters may contribute to schizophrenia
Kalkman, H. O. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.01.004 · Cited by 31
Ponzoni, L., Braida, D., Pucci, L., Donzelli, A., Fasoli, F., Manfredi, I., Papke, R. L., Stokes, C. A., Cannazza, G., Clementi, F., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3619-x · Cited by 30
Nicotine dependence – human and animal studies, current pharmacotherapies and future perspectives
Zaniewska, M., Przegaliński, E., & Filip, M. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70157-4 · Cited by 30
Pathophysiology and Clinical Implications
Shi, Y., Weingarten, T. N., Mantilla, C. B., Hooten, W. M., & Warner, D. O. (2010) · Cited by 30
Cardiovascular Events in Patients taking Varenicline
Harrison‐Woolrych, M., Maggo, S. D. S., Tan, M., Savage, R. L., & Ashton, J. (2011) · Drug Safety · doi:10.2165/11597690-000000000-00000 · Cited by 29
Bolchi, C., Valoti, E., Gotti, C., Fasoli, F., Ruggeri, P., Fumagalli, L., Binda, M., Mucchietto, V., Sciaccaluga, M., Budriesi, R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00904 · Cited by 30
Haloperidol-induced parkinsonism is attenuated by varenicline in mice
Sharma, A. K., Gupta, S., Patel, R. K., & Wardhan, N. (2018) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2017-0107 · Cited by 29
Henderson, B. J., Carper, D. J., González-Cestari, T. F., Yi, B., Mahasenan, K. V., Pavlovicz, R. E., Dalefield, M. L., Coleman, R. S., Li, C., & McKay, D. B. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201294r · Cited by 30
Sofuoglu, M., Herman, A. I., Li, Y., & Waters, A. J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2763-4 · Cited by 29
Richardson, J. L., Stephens, S., Yates, L. M., Diav‐Citrin, O., Arnon, J., Beghin, D., Kayser, A., Kennedy, D. S., Cupitt, D., Winkel, B. T., et al. (2016) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.11.010 · Cited by 28
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington’s Disease
D’Souza, G. X., & Waldvogel, H. J. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160200 · Cited by 28
Advances in Pharmacotherapy Development: Human Clinical Studies
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 29
Grodin, E. N., & Ray, L. A. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14167 · Cited by 27
Ondachi, P. W., Castro, A., Luetje, C. W., Damaj, M. I., Mascarella, S. W., Navarro, H. A., & Carroll, F. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300575y · Cited by 28
Noribogaine reduces nicotine self-administration in rats
Chang, Q., Hanania, T., Mash, D. C., & Maillet, É. L. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115584461 · Cited by 28
Patterns of nicotinic receptor antagonism II: Cardiovascular effects in rats
Jutkiewicz, E. M., Rice, K. C., Carroll, F. I., & Woods, J. H. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.021 · Cited by 28
Smoking Cessation: An Overview of Treatment Options with a Focus on Varenicline
Stack, N. M. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.11.1550 · Cited by 28
Kruk-Słomka, M., Budzyńska, B., & Biała, G. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70904-0 · Cited by 29
Mello, N. K., Fivel, P. A., Kohut, S. J., & Carroll, F. I. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.325 · Cited by 26
de Moura, F. B., & McMahon, L. R. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4514-4 · Cited by 29
Association of nAChR gene haplotypes with heavy alcohol use and body mass
Landgren, S., Engel, J. A., Andersson, M. E., González‐Quintela, A., Franco, J. C., Nilsson, S., Zetterberg, H., Blennow, K., & Jerlhag, E. (2009) · Brain Research · doi:10.1016/j.brainres.2009.08.026 · Cited by 27
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation
Mohamed, T. S., Jayakar, S. S., & Hamouda, A. K. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00071 · Cited by 27
Bolchi, C., Gotti, C., Binda, M., Fumagalli, L., Pucci, L., Pistillo, F., Vistoli, G., Valoti, E., & Pallavicini, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200937t · Cited by 27
Titus, D. J., Johnstone, T. B. C., Johnson, N. H., London, S. H., Chapalamadugu, M., Hogenkamp, D. J., Gee, K. W., & Atkins, C. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223180 · Cited by 27
Kozikowski, A. P., Chellappan, S. K., Xiao, Y., Bajjuri, K. M., Yuan, H., Kellar, K. J., & Petukhov, P. A. (2007) · ChemMedChem · doi:10.1002/cmdc.200700073 · Cited by 28
Nicotinic Receptors Containing the α7 Subunit: A Model for Rational Drug Design
Sharma, G., & Vijayaraghavan, S. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786848703 · Cited by 27
Roh, S., Hoeppner, S. S., Schoenfeld, D., Fullerton, C. A., Stoeckel, L. E., & Evins, A. E. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3286-3 · Cited by 28
Concurrent access to nicotine and sucrose in rats
Panlilio, L. V., Hogarth, L., & Shoaib, M. C. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3787-8 · Cited by 26
Boggs, D. L., Carlson, J., Cortes-Briones, J., Krystal, J. H., & D’Souza, D. C. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131216121019 · Cited by 26
Lange‐Asschenfeldt, C., Schäble, S., Suvorava, T., Gholamreza-Fahimi, E., Bisha, M., Stermann, T., Henning, U., & Kojda, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.025 · Cited by 26
Arias, H. R., Feuerbach, D., Targowska‐Duda, K. M., Kaczor, A. A., Poso, A., & Jóźwiak, K. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.11.003 · Cited by 25
Introductory Chapter: Plant Extracts
Dekebo, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85493 · Cited by 25
Dissociation of tolerance and nicotine withdrawal-associated deficits in contextual fear
Gould, T. J., Wilkinson, D. S., Yildirim, E., Blendy, J. A., & Adoff, M. D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.02.038 · Cited by 26
Cunningham, C. S., & McMahon, L. R. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.003 · Cited by 24
Malysz, J., Grønlien, J. H., Timmermann, D. B., Håkerud, M., Thorin‐Hagene, K., Ween, H., Trumbull, J. D., Xiong, Y., Briggs, C. A., Ahring, P. K., et al. (2009) · Assay and Drug Development Technologies · doi:10.1089/adt.2009.0194 · Cited by 25
Terry, A. V., Plagenhoef, M. R., & Callahan, P. M. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4154-0 · Cited by 24
Lacroix, F., Pettorelli, A., Maddux, J.-M. N., Heidari-Jam, A., & Chaudhri, N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.254 · Cited by 24
Pflugfelder, S. C., Cao, A. C., Galor, A., Nichols, K. K., Cohen, N. A., & Dalton, M. (2022) · The Ocular Surface · doi:10.1016/j.jtos.2022.05.001 · Cited by 24
Biała, G., & Staniak, N. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.04.022 · Cited by 23
Is it safe to use smoking cessation therapeutics during pregnancy?
Long, N. E. D., Barra, N. G., Hardy, D. B., & Holloway, A. C. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.973846 · Cited by 23
Emerging preclinical pharmacological targets for Parkinson's disease
More, S. V., & Choi, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8104 · Cited by 24
Perkins, K. A., Mercincavage, M., Fonte, C. A., & Lerman, C. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1816-9 · Cited by 23
Effect of varenicline on aspects of inhibitory control in smokers
Austin, A. J., Duka, T., Rusted, J. M., & Jackson, A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3512-7 · Cited by 23
Varenicline Interactions at the 5-HT3 Receptor Ligand Binding Site are Revealed by 5-HTBP
Price, K. L., Lillestøl, R., Ulens, C., & Lummis, S. C. R. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500369h · Cited by 22
Adams, T. R., Arnsten, J. H., Ning, Y. M., & Nahvi, S. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1370746 · Cited by 25
Xi, Z. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6299 · Cited by 26
Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats
Crunelle, C. L., Schulz, S., de Bruin, K. M., Miller, M. L., van den Brink, W., & Booij, J. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.001 · Cited by 23
Ortiz, N. C., O'Neill, H. C., Marks, M. J., & Grady, S. R. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr284 · Cited by 22
Ren, J. T., Ding, X., & Greer, J. J. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003128 · Cited by 22
Peng, C., Stokes, C. A., Mineur, Y. S., Picciotto, M. R., Tian, C., Eibl, C., Tomassoli, I., Guendisch, D., & Papke, R. L. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.206904 · Cited by 21
Rahman, S., Zhang, Z., Papke, R. L., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707612 · Cited by 22
Zesiewicz, T. A., Sullivan, K. L., Gooch, C. L., & Lynch, D. R. (2009) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0b013e3181910074 · Cited by 22
Cameli, C., Bacchelli, E., Paola, M. D., Giucastro, G., Cifiello, S., Collo, G., Cainazzo, M. M., Pini, L. A., Maestrini, E., & Zoli, M. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0223-2 · Cited by 23
Corley, C. L., Craig, A. J., Sadek, S. M., Marusich, J. A., Chehimi, S. N., White, A. M., Holdiness, L. J., Reiner, B. C., & Gipson, C. D. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173836 · Cited by 23
Cardiovascular effects of pharmacologic therapies for smoking cessation
Sobieraj, D. M., White, W. B., & Baker, W. L. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.11.003 · Cited by 21
Varenicline for smoking cessation
Tonstad, S. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.121 · Cited by 21
Oon‐arom, A., Likhitsathain, S., & Srisurapanont, M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107631 · Cited by 21
Varenicline and P50 auditory gating in medicated schizophrenic patients: A pilot study
Waldo, M. C., Woodward, L., & Adler, L. E. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2009.01.025 · Cited by 21
Pivavarchyk, M., Smith, A. M., Zhang, Z., Zhou, D., Wang, X., Toyooka, N., Tsuneki, H., Sasaoka, T., McIntosh, J. M., Crooks, P. A., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.02.018 · Cited by 21
Hansen, C. P., Jensen, A. A., Christensen, J. K., Balle, T., Liljefors, T., & Frølund, B. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701625v · Cited by 21
Varenicline-induced Mixed Mood and Psychotic Episode in a Patient with Schizoaffective Disorder
Liu, M., Tsai, S., & Yang, S.-T. (2009) · CNS Spectrums · doi:10.1017/s1092852900022975 · Cited by 21
Emerging drugs for schizophrenia
Biedermann, F., & Fleischhacker, W. W. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.556112 · Cited by 20
Harrison‐Woolrych, M., Paterson, H., & Tan, M. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3489 · Cited by 20
Sutherland, M. T., Carroll, A. J., Salmeron, B. J., Ross, T. J., Hong, L. E., & Stein, E. A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.10.043 · Cited by 20
Cognition as a therapeutic target in late-life depression: Potential for nicotinic therapeutics
Zurkovsky, L., Taylor, W. D., & NEWHOUSE, P. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.032 · Cited by 20
Stoker, A. K., & Markou, A. (2015) · Current topics in behavioral neurosciences · doi:10.1007/978-3-319-13482-6_5 · Cited by 22
Perkins, K. A., Chengappa, K. N. R., Karelitz, J. L., Boldry, M. C., Michael, V., Herb, T., Gannon, J. M., Brar, J. S., Ford, L., Rassnick, S., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.292 · Cited by 20
An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine
Wilkinson, J., Carroll, F. I., & Bevins, R. A. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102518 · Cited by 19
Kombo, D. C., Mazurov, A. A., Tallapragada, K., Hammond, P. S., Chewning, J., Hauser, T. A., Vásquez-Valdivieso, M. G., Yohannes, D., Talley, T. T., Taylor, P., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.09.033 · Cited by 19
Ciudad‐Roberts, A., Camarasa, J., Pubill, D., & Escubedo, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.02.013 · Cited by 19
Cunningham, C. S., & McMahon, L. R. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3037-5 · Cited by 19
DuBois, D. W., Damborsky, J. C., Fincher, A. S., Frye, G. D., & Winzer‐Serhan, U. H. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.12.013 · Cited by 19
Novel multifunctional pharmacology of lobinaline, the major alkaloid from Lobelia cardinalis
Brown, D., Rogers, D. T., Pomerleau, F., Siripurapu, K. B., Kulshrestha, M., Gerhardt, G. A., & Littleton, J. M. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.04.013 · Cited by 19
Review: Pharmacotherapy for smoking cessation
Carrozzi, L., Pistelli, F., & Viegi, G. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808096136 · Cited by 19
Varenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL/6J mice
Kamens, H. M., Silva, C. P., Peck, C., & Miller, C. N. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.07.020 · Cited by 19
Micoulaud, F. G. (2015) · Journal of Clinical Research & Bioethics · doi:10.4172/2155-9627.1000213 · Cited by 25
Potasiewicz, A., Gołębiowska, J., Popik, P., & Nikiforuk, A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118812097 · Cited by 19
Varenicline use in patients with mental illness: an update of the evidence
Purvis, T. L., Nelson, L. A., & Mambourg, S. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003657133 · Cited by 19
Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline
Schassburger, R. L., Levin, M. E., Weaver, M. T., Palmatier, M. I., Caggiula, A. R., Donny, E. C., & Sved, A. F. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3732-x · Cited by 19
Scuppa, G., Cippitelli, A., Toll, L., Ciccocioppo, R., & Ubaldi, M. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.09.002 · Cited by 19
Arnam, E. B. V., Blythe, E. E., Lester, H. A., & Dougherty, D. A. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.085795 · Cited by 18
Mouse model predicts effects of smoking and varenicline on event-related potentials in humans
Rudnick, N. D., Strasser, A. A., Phillips, J. M., Jepson, C., Patterson, F., Frey, J. M., Turetsky, B. I., Lerman, C. E., & Siegel, S. J. (2010) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntq049 · Cited by 17
Srisontiyakul, J., Kastman, H. E., Krstew, E., Govitrapong, P., & Lawrence, A. J. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2045-3 · Cited by 18
Perkins, F. N., & Freeman, K. B. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.06.015 · Cited by 21
Roberts, W., & McKee, S. A. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000161 · Cited by 18
Barış, E., Efe, H., Gümüştekin, M., Arıcı, A., & Tosun, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.721533 · Cited by 18
Varenicline in smoking cessation
Tonstad, S., & Rollema, H. (2010) · Expert Review of Respiratory Medicine · doi:10.1586/ers.10.27 · Cited by 18
Benes, F. M. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_13 · Cited by 17
Metadata
- Authors
- Mihalak, K. B., Carroll, F. I., & Luetje, C. W.
- Affiliations
- University of Miami (US)
- RTI International (US)
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 70
- Issue
- 3
- Pages
- 801-805
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2141246891
- Cited by
- 558
- References
- 26
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 7 · 2023: 23 · 2022: 14 · 2021: 15 · 2020: 20 · 2019: 19 · 2018: 22 · 2017: 32 · 2016: 41 · 2015: 40 · 2014: 44 · 2013: 48 · 2012: 36
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Miami
- U.S. Food and Drug Administration
- National Heart, Lung, and Blood Institute (T32HL007188)
- National Institute of Mental Health (MH-66038, R01MH066038)
- National Institute on Drug Abuse (R01DA012001, DA12001, DA08102, R01DA008102)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- varenicline, neuronal nicotinic acetylcholine receptors, alpha4beta2 receptor, partial agonists, full agonists, receptor selectivity, smoking cessation, cytisine derivatives
- MeSH terms
- Varenicline, Animals, Benzazepines, Neurons, Oocytes, Quinoxalines, Receptors, Nicotinic, Xenopus laevis, Nicotinic Agonists, Rats, alpha7 Nicotinic Acetylcholine Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
